Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.72 |
| ▸ | HCK | P08631 | 10/20 | 0.72 |
| ▸ | LCK | P06239 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 4/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205442 | 0.84 | BTK (1.00) | BTKHCKITK | |
| SCHEMBL19205329 | 0.84 | BTK (1.00) | BTKHCKITK | |
| SCHEMBL19205330 | 0.84 | BTK (1.00) | BTKHCKITK | |
| SCHEMBL19205449 | 0.81 | BTK (1.00) | BTKHCK | |
| SCHEMBL19205363 | 0.81 | BTK (1.00) | BTKHCK | |
| SCHEMBL19205357 | 0.81 | BTK (1.00) | BTKHCK | |
| SCHEMBL19205412 | 0.81 | BTK (1.00) | BTKHCK | |
| SCHEMBL19229776 | 0.80 | BTK (0.75) | BTKHCKLCKITKAURKB | |
| SCHEMBL22474765 | 0.75 | HCK (0.61) | BTKHCKLCKITKAURKB | |
| SCHEMBL22474750 | 0.71 | HCK (0.60) | BTKHCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, MCL1 | BTK 1/4885HCK 6/4885LCK 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.